Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, March 31, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -486.88%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-293.33%
RETURN ON EQUITY (ROE) AVG 3Y
-290.16%
RETURN ON EQUITY (ROE) AVG 5Y
-209.12%
RETURN ON EQUITY (ROE) AVG 10Y
-120.76%
RETURN ON EQUITY (ROE) AVG 15Y
-96.58%
RETURN ON EQUITY (ROE) AVG 20Y
-78.67%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Achieve Life Sciences, Inc.
Market Cap
$717.21M
Return on Equity (ROE)
N/A
TTM Avg
-293.33%
3Y Avg
-290.16%
5Y Avg
-209.12%
Market Cap
$706.08M
Return on Equity (ROE)
15.36%
TTM Avg
25.54%
3Y Avg
15.72%
5Y Avg
18.75%
Market Cap
$723.83M
Return on Equity (ROE)
-22.36%
TTM Avg
-60.32%
3Y Avg
-42.71%
5Y Avg
-132.49%
Market Cap
$695.21M
Return on Equity (ROE)
-41.20%
TTM Avg
50554.28%
3Y Avg
25132.94%
5Y Avg
16622.35%
Market Cap
$743.96M
Return on Equity (ROE)
-70.19%
TTM Avg
-78.37%
3Y Avg
-123.45%
5Y Avg
-79.18%
Market Cap
$727.72M
Return on Equity (ROE)
-25.03%
TTM Avg
-10.49%
3Y Avg
-5.87%
5Y Avg
-23.97%
Market Cap
$747.00M
Return on Equity (ROE)
-40.21%
TTM Avg
-52.14%
3Y Avg
-52.14%
5Y Avg
-52.14%
Market Cap
$745.42M
Return on Equity (ROE)
-35.07%
TTM Avg
-26.66%
3Y Avg
-24.19%
5Y Avg
-5.48%
Market Cap
$678.96M
Return on Equity (ROE)
-113.05%
TTM Avg
-95.98%
3Y Avg
-72.88%
5Y Avg
-73.85%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Achieve Life Sciences, Inc. (ACHV) | $717.21M | N/A | -293.33% | -290.16% | -209.12% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $706.08M | 15.36% | 25.54% | 15.72% | 18.75% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $723.83M | -22.36% | -60.32% | -42.71% | -132.49% |
| Anteris Technologies Global Corp. (AVR)vs › | $695.21M | -41.20% | 50554.28% | 25132.94% | 16622.35% |
| Candel Therapeutics, Inc. (CADL)vs › | $743.96M | -70.19% | -78.37% | -123.45% | -79.18% |
| Cytek Biosciences, Inc. (CTKB)vs › | $727.72M | -25.03% | -10.49% | -5.87% | -23.97% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $747.00M | -40.21% | -52.14% | -52.14% | -52.14% |
| Design Therapeutics, Inc. (DSGN)vs › | $745.42M | -35.07% | -26.66% | -24.19% | -5.48% |
| Faeth Therapeutics, Inc. (FTH)vs › | $678.96M | -113.05% | -95.98% | -72.88% | -73.85% |
| MiMedx Group, Inc. (MDXG)vs › | $664.59M | 2.89% | 20.45% | 11.91% | -3.26% |
ROE
N/A
ROA
-59.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -486.88% |
| 2025-12-31 | -253.96% |
| 2025-09-30 | -155.72% |
| 2025-06-30 | -121.00% |
| 2025-03-31 | -449.07% |
| 2024-12-31 | -190.57% |
| 2024-09-30 | -104.99% |
| 2024-06-30 | -65.13% |
| 2024-03-31 | -55.23% |
| 2023-09-30 | -880.91% |
| 2023-06-30 | -428.29% |
| 2022-12-31 | -510.06% |
| 2022-06-30 | -242.16% |
| 2022-03-31 | -152.69% |
| 2021-12-31 | -118.22% |
| 2021-09-30 | -88.54% |
| 2021-06-30 | -68.04% |
| 2021-03-31 | -64.51% |
| 2020-12-31 | -39.51% |
| 2020-09-30 | -51.41% |
| 2020-06-30 | -90.17% |
| 2020-03-31 | -92.17% |
| 2019-12-31 | -90.83% |
| 2019-09-30 | -206.83% |
| 2019-06-30 | -142.60% |
| 2019-03-31 | -152.80% |
| 2018-12-31 | -80.29% |
| 2018-09-30 | -90.30% |
| 2018-06-30 | -97.45% |
| 2018-03-31 | -264.26% |
| 2017-12-31 | -209.14% |
| 2017-09-30 | -173.95% |
| 2017-06-30 | -120.58% |
| 2017-03-31 | -123.91% |
| 2016-12-31 | -106.13% |
| 2016-09-30 | -65.56% |
| 2016-06-30 | -59.71% |
| 2016-03-31 | -46.73% |
| 2015-12-31 | -44.87% |
| 2015-09-30 | -53.54% |
| 2015-06-30 | -74.90% |
| 2015-03-31 | -73.69% |
| 2014-12-31 | -77.04% |
| 2014-09-30 | -70.10% |
| 2014-06-30 | -122.36% |
| 2014-03-31 | -114.13% |
| 2013-12-31 | -85.59% |
| 2013-09-30 | -67.23% |
| 2013-06-30 | -47.72% |
| 2013-03-31 | -34.74% |
| 2012-12-31 | -31.87% |
| 2012-09-30 | -38.08% |
| 2012-06-30 | -21.65% |
| 2012-03-31 | -23.67% |
| 2011-12-31 | -47.50% |
| 2011-09-30 | -19.75% |
| 2011-06-30 | -54.74% |
| 2011-03-31 | -30.33% |
| 2010-12-31 | -28.52% |
| 2010-09-30 | -41.27% |
| 2010-06-30 | -6.67% |
| 2010-03-31 | -30.15% |
| 2009-12-31 | -23.85% |
| 2009-09-30 | -130.02% |
| 2009-06-30 | -186.67% |
| 2009-03-31 | -78.56% |
| 2008-12-31 | -77.53% |
| 2008-09-30 | -9.12% |
| 2008-06-30 | -48.12% |
| 2008-03-31 | -49.65% |
| 2007-12-31 | -40.94% |
| 2007-09-30 | -74.39% |
| 2007-06-30 | -63.69% |
| 2007-03-31 | -53.23% |
| 2006-12-31 | -54.72% |
| 2006-09-30 | -40.39% |
| 2006-06-30 | -40.86% |
| 2006-03-31 | -70.56% |
| 2005-12-31 | -59.83% |
| 2005-09-30 | -121.40% |
| 2005-06-30 | -171.95% |
| 2005-03-31 | -122.06% |
| 2004-12-31 | -85.50% |
| 2004-09-30 | -55.51% |
| 2004-06-30 | -44.55% |
| 2004-03-31 | -70.62% |
| 2003-12-31 | -54.21% |
| 2003-09-30 | -48.56% |
| 2003-06-30 | -106.08% |
